human | Q5 |
P496 | ORCID iD | 0000-0002-4092-8925 |
P69 | educated at | Leiden University | Q156598 |
P108 | employer | The Feinstein Institute for Medical Research | Q7733638 |
P735 | given name | Jolien | Q21647026 |
Jolien | Q21647026 | ||
P106 | occupation | researcher | Q1650915 |
Q58234722 | Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses |
Q44288937 | Activation of human basophils by combined toll-like receptor- and FcεRI-triggering can promote Th2 skewing of naive T helper cells |
Q27024588 | Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity |
Q34700290 | Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. |
Q51063130 | Communication between human mast cells and CD4(+) T cells through antigen-dependent interactions. |
Q41494236 | Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering. |
Q48258497 | Expansion of Th17 Cells by Human Mast Cells Is Driven by Inflammasome-Independent IL-1β. |
Q40010797 | Human mast cells costimulate T cells through a CD28-independent interaction |
Q44056900 | IgE and IL-33-mediated triggering of human basophils inhibits TLR4-induced monocyte activation. |
Q42575994 | Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium |
Q38460407 | Mast cells in rheumatic disease. |
Q58223827 | Repeated FcεRI triggering reveals modified mast cell function related to chronic allergic responses in tissue |
Q39371149 | The production and secretion of complement component C1q by human mast cells |
Q38391522 | Therapeutics to block autoantibody initiation and propagation in systemic lupus erythematosus and rheumatoid arthritis. |
Q58234718 | Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies |
Search more.